106 related articles for article (PubMed ID: 22318162)
1. Determining the optimal newborn screening protocol for cystic fibrosis.
Southern KW
Thorax; 2012 Apr; 67(4):281-2. PubMed ID: 22318162
[No Abstract] [Full Text] [Related]
2. Blood concentrations of pancreatitis associated protein in neonates: relevance to neonatal screening for cystic fibrosis.
Sarles J; Barthellemy S; Férec C; Iovanna J; Roussey M; Farriaux JP; Toutain A; Berthelot J; Maurin N; Codet JP; Berthézène P; Dagorn JC
Arch Dis Child Fetal Neonatal Ed; 1999 Mar; 80(2):F118-22. PubMed ID: 10325788
[TBL] [Abstract][Full Text] [Related]
3. Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany.
Sommerburg O; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Stopsack M; Gahr M; Hoffmann GF; Mall MA
Pediatr Pulmonol; 2015 Jul; 50(7):655-64. PubMed ID: 25914230
[TBL] [Abstract][Full Text] [Related]
4. PAP assays in newborn screening for cystic fibrosis: a population-based cost-effectiveness study.
Seror V; Cao C; Roussey M; Giorgi R
J Med Screen; 2016 Jun; 23(2):62-9. PubMed ID: 26304152
[TBL] [Abstract][Full Text] [Related]
5. Positive neonatal screening for cystic fibrosis in neonates with renal failure.
Oosterveld MJ; Schilperoort JV; Lilien MR; Arets HG
Thorax; 2010 Jul; 65(7):652-3. PubMed ID: 20627926
[TBL] [Abstract][Full Text] [Related]
6. Comparison between two newborn screening strategies for cystic fibrosis in Argentina: IRT/IRT versus IRT/PAP.
Teper A; Smithuis F; Rodríguez V; Salvaggio O; Maccallini G; Aranda C; Lubovich S; Zaragoza S; García-Bournissen F
Pediatr Pulmonol; 2021 Jan; 56(1):113-119. PubMed ID: 33095477
[TBL] [Abstract][Full Text] [Related]
7. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations.
Sommerburg O; Krulisova V; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Votava F; Balascakova M; Skalicka V; Stopsack M; Gahr M; Macek M; Mall MA; Hoffmann GF
J Cyst Fibros; 2014 Jan; 13(1):15-23. PubMed ID: 23891278
[TBL] [Abstract][Full Text] [Related]
8. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
[TBL] [Abstract][Full Text] [Related]
9. A product of immunoreactive trypsinogen and pancreatitis-associated protein as second-tier strategy in cystic fibrosis newborn screening.
Weidler S; Stopsack KH; Hammermann J; Sommerburg O; Mall MA; Hoffmann GF; Kohlmüller D; Okun JG; Macek M; Votava F; Krulišová V; Balaščaková M; Skalická V; Lee-Kirsch MA; Stopsack M
J Cyst Fibros; 2016 Nov; 15(6):752-758. PubMed ID: 27461140
[TBL] [Abstract][Full Text] [Related]
10. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study.
Vernooij-van Langen AM; Loeber JG; Elvers B; Triepels RH; Gille JJ; Van der Ploeg CP; Reijntjens S; Dompeling E; Dankert-Roelse JE;
Thorax; 2012 Apr; 67(4):289-95. PubMed ID: 22271776
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study.
Nshimyumukiza L; Bois A; Daigneault P; Lands L; Laberge AM; Fournier D; Duplantie J; Giguère Y; Gekas J; Gagné C; Rousseau F; Reinharz D
J Cyst Fibros; 2014 May; 13(3):267-74. PubMed ID: 24238947
[TBL] [Abstract][Full Text] [Related]
12. Neonatal screening for cystic fibrosis: comparing the performances of IRT/DNA and IRT/PAP.
Sarles J; Giorgi R; Berthézène P; Munck A; Cheillan D; Dagorn JC; Roussey M
J Cyst Fibros; 2014 Jul; 13(4):384-90. PubMed ID: 24513262
[TBL] [Abstract][Full Text] [Related]
13. The influence of sex, gestational age, birth weight, blood transfusion, and timing of the heel prick on the pancreatitis-associated protein concentration in newborn screening for cystic fibrosis.
Vernooij-van Langen AM; Loeber JG; Elvers B; Triepels RH; Roefs J; Gille JJ; Reijntjens S; Dompeling E; Dankert-Roelse JE
J Inherit Metab Dis; 2013 Jan; 36(1):147-54. PubMed ID: 22739940
[TBL] [Abstract][Full Text] [Related]
14. Newborn screening for cystic fibrosis: do we need a second IRT?
Price JF
Arch Dis Child; 2006 Mar; 91(3):209-10. PubMed ID: 16492882
[TBL] [Abstract][Full Text] [Related]
15. Cystic fibrosis and neonatal screening.
Rodrigues R; Gabetta CS; Pedro KP; Valdetaro F; Fernandes MI; Magalhães PK; Januário JN; Maciel LM
Cad Saude Publica; 2008; 24 Suppl 4():s475-84. PubMed ID: 18797725
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Quantase neonatal immunoreactive trypsinogen (IRT) screening assay for cystic fibrosis.
Ball CL; Montgomery MD; Bridge PJ; Lyon ME
Clin Chem Lab Med; 2005; 43(5):570-2. PubMed ID: 15899682
[No Abstract] [Full Text] [Related]
17. Variation in immunoreactive trypsinogen concentrations among Michigan newborns and implications for cystic fibrosis newborn screening.
Korzeniewski SJ; Young WI; Hawkins HC; Cavanagh K; Nasr SZ; Langbo C; Teneyck KR; Grosse SD; Kleyn M; Grigorescu V
Pediatr Pulmonol; 2011 Feb; 46(2):125-30. PubMed ID: 20848586
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data.
van der Ploeg CP; van den Akker-van Marle ME; Vernooij-van Langen AM; Elvers LH; Gille JJ; Verkerk PH; Dankert-Roelse JE;
J Cyst Fibros; 2015 Mar; 14(2):194-202. PubMed ID: 25213034
[TBL] [Abstract][Full Text] [Related]
19. Newborn screening and carrier screening for cystic fibrosis: alternative or complementary?
Castellani C; Massie J
Eur Respir J; 2014 Jan; 43(1):20-3. PubMed ID: 24381320
[No Abstract] [Full Text] [Related]
20. Positive Newborn Screening for Cystic Fibrosis, What to Do Next?
Kumar P; Goyal JP
Indian J Pediatr; 2019 Dec; 86(12):1147. PubMed ID: 31325101
[No Abstract] [Full Text] [Related]
[Next] [New Search]
